Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings
Journal of Neurology · 2024-08 · 271 (8) · 5102-5108
DOI: 10.1007/s00415-024-12438-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurology, online erschienen am 29.05.2024. Verfasst von Ariel Rechtman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Laboratory of Neuroimmunology and the Agnes-Ginges Center for Neurogenetics, Hadassah-Hebrew University Medical Center, E…. Hauptthemen laut MEDLINE: Myelin-Oligodendrocyte Glycoprotein. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hebrew University of Jerusalem.
Abstract (Originalsprache)
Introduction
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified demyelinating disorder with a diverse clinical spectrum. Diagnosing MOGAD traditionally relies on clinical judgment, highlighting the necessity for precise diagnostic criteria. Banwell et al. proposed criteria, aiming to refine the diagnostic spectrum. This study evaluates these criteria in a real-life cohort, comparing their performance with clinical judgment and describe the cohort of MOGAD patients.
Methods
This retrospective study, conducted at Hadassah Medical Center, included 88 patients with MOG-IgG antibodies. Patients with a positive or borderline MOG-IgG antibodies by cell-based assay were included. Demographics, clinical and MRI data were recorded. Cases were divided into definite MOGAD and Non-MOGAD groups as determined by the treating physician. We assessed the sensitivity and specificity of the new criteria in comparison to treating physicians’ evaluations. Additionally, we examined clinical differences between the MOGAD and Non-MOGAD groups.
Results
We observed a strong concordance (98%) between the new MOGAD criteria and treating physicians' diagnoses. Clinical disparities between MOGAD and Non-MOGAD groups included lower EDSS scores, normal MRI scans, preserved brain volume, negative OCB results, and distinct relapse patterns. Also, compared to relapsing patients, monophasic MOGAD patients have greater brain volume and a lower age at onset.
Conclusion
The study demonstrates robust accuracy of new MOGAD criteria, emphasizing their potential to enhance diagnostic precision. Treatment response integration into the MOGAD diagnosis is crucial, as it could aid in distinguishing MOGAD from other demyelinating disorders. Distinct clinical profiles highlight the importance of informed decisions in managing MOGAD and similar disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Laboratory of Neuroimmunology and the Agnes-Ginges Center for Neurogenetics, Hadassah-Hebrew University Medical Center, Ein-Kerem, Germany.
- Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Department of Military Medicine, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Department of Neurology and Laboratory of Neuroimmunology and the Agnes-Ginges Center for Neurogenetics, Hadassah-Hebrew University Medical Center, Ein-Kerem, Germany. adembinsky@gmail.com.
- Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. adembinsky@gmail.com.
- Neurology Department, Multiple Sclerosis and Immunobiology Research, Hadassah Medical Center, Ein-Kerem, POB 12000, 91120, Jerusalem, Israel. adembinsky@gmail.com.
Förderung
- Hebrew University of Jerusalem
Zitieren
APA
Rechtman, A., Freidman-Korn, T., Zveik, O., Shweiki, L., Hoichman, G., & Vaknin-Dembinsky, A. (2024). Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings. Journal of Neurology, 271(8), 5102-5108. https://doi.org/10.1007/s00415-024-12438-6
Vancouver
Rechtman A, Freidman-Korn T, Zveik O, Shweiki L, Hoichman G, Vaknin-Dembinsky A. Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings. Journal of Neurology. 2024;271(8):5102-5108. doi:10.1007/s00415-024-12438-6
BibTeX
@article{Rechtman2024,
author = {Rechtman, Ariel and Freidman-Korn, Tal and Zveik, Omri and Shweiki, Lyne and Hoichman, Garrick and Vaknin-Dembinsky, Adi},
title = {Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings},
journal = {Journal of Neurology},
year = {2024},
volume = {271},
number = {8},
pages = {5102--5108},
doi = {10.1007/s00415-024-12438-6}
}
EUVIMED